In this respect, we previously observed that SrcDN expression and selective c-Src tyrosine-kinase inhibitors diminish cyclin D1 expression and cell cycle progression at G1-phase in breast cancer cells [24, 43, 44]. The gene discussed is CSK; the disease is breast cancer.